There are currently 32 active clinical trials seeking participants for Idiopathic Pulmonary Fibrosis research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and Pennsylvania.
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: UCSF Fresno, Fresno, California +57 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect
NCT06265532
Recruiting
The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/09/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
NCT05195918
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/02/2024
Locations: UCSF Parnassus, San Francisco, California +2 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Xenon MRI and Progressive ILD
NCT05241275
Recruiting
The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Duke University, Durham, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Register for Updates
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
NCT03500731
Recruiting
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
01/04/2024
Locations: UPMC Presbyterian, Pittsburgh, Pennsylvania +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Register for Updates
Mechanisms of Familial Pulmonary Fibrosis
NCT03437486
Recruiting
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form of idiopathic pulmonary fibrosis (IPF), which is defined as 2 or more bloodline relatives which have a diagnosis of idiopathic interstitial pneumonia (IIP). The most common form of idiopathic interstitial pneumonia in FIP families is IPF (approximately 70%). The inheritance pattern in FIP is consistent with autosomal dominant inheritance... Read More
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
12/11/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Familial Interstitial Pneumonia
Register for Updates
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
NCT00470327
Recruiting
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Register for Updates
Interstitial Lung Disease Research Unit Biobank
NCT05392881
Recruiting
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Hypersensitivity Pneumonitis
Register for Updates
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00373841
Recruiting
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Michelle F MacPherson, Pittsburgh, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
The Effect of N115 on Coughing in IPF Patients
NCT06037408
Recruiting
The purpose of this clinical trial is to administer a sodium pyruvate nasal spray that eliminates nasal oxidative stresses, caused by oxygen radicals, and demonstrate the efficacy of sodium pyruvate to reduce coughing and increase lung functions in patients with idiopathic pulmonary fibrosis. This will be a 21-day double-blinded randomized placebo-controlled trial designed to determine if patients with idiopathic pulmonary fibrosis treated with 20mM sodium pyruvate in 0.9% sodium chloride nasal... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
09/16/2023
Locations: Family First Medical Research Center, Hialeah Gardens, Florida
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT05954988
Recruiting
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
Gender:
All
Ages:
40 years and above
Trial Updated:
08/29/2023
Locations: University of Alabama, Birmingham, Alabama +6 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study of Patients With Chronic Disease
NCT04263727
Recruiting
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.
Gender:
All
Ages:
All
Trial Updated:
08/24/2023
Locations: Asthma and Allergy Associates, PC, Colorado Springs, Colorado +4 locations
Conditions: Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Register for Updates